Jones Financial Companies Lllp Sells 45,375 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Jones Financial Companies Lllp reduced its stake in Thermo Fisher Scientific Inc. by 52.2% in Q1, now holding 41,540 shares worth approximately $20.67 million.
• In addition to Jones Financial, several institutional investors have increased their stakes, with Revolve Wealth Partners LLC raising its position by 4.2% in Q4.
• CEO Marc N. Casper sold 10,000 shares on August 22nd, representing a 7.99% decrease in his ownership, while insiders sold a total of 29,666 shares in the last ninety days.

Jones Financial Companies Lllp lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 52.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 41,540 shares of the medical research company's stock after selling 45,375 shares during the quarter. Jones Financial Companies Lllp's holdings in Thermo Fisher Scientific were worth $20,670,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Mondrian Investment Partners LTD boosted its position in Thermo Fisher Scientific by 146.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock worth $106,738,000 after acquiring an additional 127,357 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Thermo Fisher Scientific by 22.0% during the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock worth $2,419,000 after purchasing an additional 877 shares in the last quarter. Cetera Trust Company N.A raised its stake in shares of Thermo Fisher Scientific by 3.3% during the 1st quarter. Cetera Trust Company N.A now owns 4,646 shares of the medical research company's stock worth $2,312,000 after purchasing an additional 150 shares in the last quarter. Philip James Wealth Mangement LLC bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $268,000. Finally, Security National Bank of SO Dak raised its stake in shares of Thermo Fisher Scientific by 0.8% during the 4th quarter. Security National Bank of SO Dak now owns 8,726 shares of the medical research company's stock worth $4,540,000 after purchasing an additional 73 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on TMO. UBS Group upped their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. Wall Street Zen cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a report on Friday, July 11th. Wells Fargo & Company dropped their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research note on Thursday, July 24th. Finally, HSBC restated a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $589.38.

Thermo Fisher Scientific Stock Performance

TMO stock traded down $5.38 during trading hours on Wednesday, hitting $477.03. 1,442,085 shares of the stock were exchanged, compared to its average volume of 1,608,466. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $180.13 billion, a P/E ratio of 27.59, a P/E/G ratio of 2.58 and a beta of 0.75. The company has a 50-day simple moving average of $464.58 and a two-hundred day simple moving average of $452.37. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $623.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter last year, the business earned $5.37 EPS. The company's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,066 shares of company stock worth $14,182,963. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.